UPPTHERA
- Employees
- 11–50
- Business Model
- B2B
- Website
- uppthera.com
About
UPPTHERA is a South Korean pharmaceutical venture company developing innovative cancer therapeutics based on targeted protein degradation (TPD) technology, including PROTACs. The company has built proprietary platforms — UPPGRADER for novel E3 ligase target identification using scRNA-seq analysis, UPPBEAT for covalent ligand screening via chemoproteomics, and SpeedUPP for accelerating hit-to-candidate timelines — enabling it to pursue oncology targets previously considered undruggable. UPPTHERA has entered Phase 1/2a clinical trials with its lead PLK1-targeting degrader for small cell lung cancer and has secured partnerships and investments from firms including YuanBio Venture Capital and Boryung Pharmaceutical.
Summary
UPPTHERA is a Biotech company based in South Korea.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/uppthera"><img src="https://indexed.vc/api/badge/company/uppthera" alt="UPPTHERA on Indexed.vc" width="260" height="76" /></a>